Riptide peptide turns TAMs proinflammatory

Riptide unveils preclinical pancreatic cancer data, shows candidate reprograms TAMs

Riptide has lifted the curtain on its first immuno-oncology program, RP-182, which comprises an engineered peptide that reprograms tumor-associated macrophages to become proinflammatory.

Strategies to convert immunosuppressive macrophages into proinflammatory cells have been gaining momentum as a way to simultaneously

Read the full 406 word article

How to gain access

Continue reading with a
two-week free trial.